{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:47:59Z","timestamp":1779223679946,"version":"3.51.4"},"reference-count":14,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":327,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1111\/ijcp.12521","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T08:11:56Z","timestamp":1412842316000},"page":"1503-1507","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures"],"prefix":"10.1155","volume":"68","author":[{"given":"J. D.","family":"Hirsch","sequence":"first","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences; University of California San Diego; La Jolla CA USA"},{"name":"Veterans Affairs San Diego Healthcare System; San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gnanasakthy","sequence":"additional","affiliation":[{"name":"RTI Health Solutions 3040 Cornwallis Road Research Triangle Park NC 27709-2194 United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Lale","sequence":"additional","affiliation":[{"name":"Health Services Research Center; University of California San Diego; La Jolla CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Choi","sequence":"additional","affiliation":[{"name":"Health Services Research Center; University of California San Diego; La Jolla CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Sarkin","sequence":"additional","affiliation":[{"name":"Health Services Research Center; University of California San Diego; La Jolla CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,10,9]]},"reference":[{"key":"10.1111\/ijcp.12521-BIB0001|ijcp12521-cit-0001","first-page":"S443","article-title":"Diagnosis of gout: clinical, laboratory, and radiologic findings","volume":"11","author":"Schlesinger","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1111\/ijcp.12521-BIB0002|ijcp12521-cit-0002","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/14656560902950742","article-title":"Gout: what are the treatment options?","volume":"10","author":"Schlesinger","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/ijcp.12521-BIB0003|ijcp12521-cit-0003","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1111\/ijcp.12521-BIB0004|ijcp12521-cit-0004","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3949\/ccjm.75.Suppl_5.S5","article-title":"Clinical manifestations of hyperuricemia and gout","volume":"75","author":"Mandell","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1111\/ijcp.12521-BIB0005|ijcp12521-cit-0005","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"Quality of life and disability in patients with treatment-failure gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1111\/ijcp.12521-BIB0006|ijcp12521-cit-0006","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/01.rhu.0000147049.12220.32","article-title":"Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting","volume":"10","author":"Riedel","year":"2004","journal-title":"J Clin Rheumatol"},{"key":"10.1111\/ijcp.12521-BIB0007|ijcp12521-cit-0007","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/ijcp.12521-BIB0008|ijcp12521-cit-0008","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3899\/jrheum.110274","article-title":"Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials","volume":"38","author":"Taylor","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1111\/ijcp.12521-BIB0009|ijcp12521-cit-0009","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3899\/jrheum.080506","article-title":"Evaluation of an instrument assessing influence of gout on health-related quality of life","volume":"35","author":"Hirsch","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1111\/ijcp.12521-BIB0010|ijcp12521-cit-0010","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis","volume":"43","author":"Kosinski","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1111\/ijcp.12521-BIB0011|ijcp12521-cit-0011","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/rheumatology\/ker023","article-title":"Minimally important differences of the gout impact scale in a randomized controlled trial","volume":"50","author":"Khanna","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/ijcp.12521-BIB0012|ijcp12521-cit-0012","first-page":"167","article-title":"The Stanford health assessment questionnaire (HAQ): a review of its history, issues, progress, and documentation","volume":"30","author":"Bruce","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1111\/ijcp.12521-BIB0013|ijcp12521-cit-0013","doi-asserted-by":"crossref","DOI":"10.4236\/ojra.2013.33024","article-title":"A composite endpoint measure to consolidate multidimensional impact of treatment on gouty arthritis","author":"Sarkin","year":"2013","journal-title":"Open J Rheumatol Autoimmun Dis"},{"key":"10.1111\/ijcp.12521-BIB0014|ijcp12521-cit-0014","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1517\/14712598.2012.705825","article-title":"Canakinumab in gout","volume":"12","author":"Schlesinger","year":"2012","journal-title":"Expert Opin Biol Ther"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12521","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:06:52Z","timestamp":1643350012000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,9]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12521","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10,9]]},"assertion":[{"value":"2014-07-16","name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}